Cancellation of state registration. Crixivan

May 19, 2016

Active substances:

Indinavir

Trade names:

Crixivan®

ICD-10:

I.B20-B24.B24 Disease caused by human immunodeficiency virus [HIV], unspecified

I.B20-B24.B23 Disease caused by the human immunodeficiency virus [HIV], manifested as other conditions

I.B20-B24.B21 Disease caused by human immunodeficiency virus [HIV], manifested as malignant neoplasms

I.B20-B24.B20 Disease caused by the human immunodeficiency virus [HIV], manifested as infectious and parasitic diseases

Cryxivan, indinavir, HIV, a disease caused by the human immunodeficiency virus, an antiviral [HIV] agent

The Ministry of Health of the Russian Federation, in accordance with Article 32 of Federal Law No. 61-FZ of 12.04.2010 "On the circulation of medicinal products", decided to abolish state registration and exclude from the state register of medicinal products for medical use of the medicinal product (registration certificate P N011421 / 02 from 09.04.2008, issued by Merck Sharp and Doum B.V., the Netherlands):

Crixivan

(trade name of the medicinal product)

Indinavir

(international non-proprietary or chemical name of the medicinal product)

capsules, 200 mg, 400 mg

(dosage form, dosage)

Merck Sharp and Doum BV, Netherlands Waarderweg 39, 2031 BN Haarlem, the Netherlands

(name and address of the location of the manufacturer of the medicinal product)

on the basis of an application by the authorized legal entity of the company LLC "MSD Pharmaceuticals" to cancel the state registration of the medicinal product.